HEALTH CANADA approved the Aptima HPV 16 18/45 genotype assay for use on the Panther system, both developed by Hologic Inc. The assay is the only approved test for genotyping human papillomavirus types 16, 18 and/or 45 in Canada.
DEFINIENS and Clarient Diagnostic Services Inc. signed an agreement to extend the use of Definiens' automated image analysis software and solutions in Clarient's validated clinical applications for immunohistochemistry testing in breast cancer.
THE UNIVERSITY OF PITTSBURGH selected GenomOncology's GenomAnalytics platform and services to explore and mine the data in The Cancer Genome Atlas.
SARAH CANNON CANCER CENTER and HealthONE hospitals launched an initiative to fully integrate their cancer programs by the end of 2014.
RICHARD FOLKERS was named director of communications for the Foundation for the NIH.
DANA-FARBER CANCER INSTITUTE was awarded a $900,000 grant from the Ovarian Cancer Research Fund to test new combinations of targeted drugs against the disease.
THE NATIONAL COALITION FOR CANCER RESEARCH elected members to its board of directors. Wendy Selig was elected president.
AVEO Oncology and Astellas Pharma Inc. discontinued a phase II study of tivozanib in locally recurrent or metastatic triple-negative breast cancer due to insufficient enrollment.
CVS Caremark plans to stop selling cigarettes and other tobacco products at more than 7,600 CVS/pharmacy stores by Oct. 1.
Responding to questions from The Cancer Letter, Jim Newman, director of external communications at MD Anderson, confirmed that the presentation obtained by The Cancer Letter was prepared under a contract by McKinsey & Company.
